Inclusion Criteria
Concurrent Medication:
Allowed:
- Zidovudine (AZT) < 600 mg/day.
- Experimental maintenance or prophylactic therapy with an approved therapeutic agent for a non-viral opportunistic infection.
- Trimethoprim / sulfamethoxazole (TMP / SMX).
- Pyrimethamine / sulfadoxine.
- Aerosolized pentamidine.
- Ketoconazole.
- Flucytosine (5-FC).
- Antituberculosis therapy.
Concurrent Treatment:
Allowed:
- Maintenance phase of ganciclovir (DHPG) therapy.
Patients must have:
- AIDS with documented ophthalmologic findings consistent with cytomegalovirus (CMV) retinitis whose retinal lesions are less than 750 microns from the fovea and who have visual symptoms of CMV retinitis.
- Completed the treatment induction phase with ganciclovir (DHPG) and be about to participate in the maintenance phase DHPG therapy.
- Expected survival of = or > 6 months.
- Willingness and ability to give written informed consent. A copy of the signed and witnessed consent form must be maintained with the investigator's study files.
- Seropositive for the presence of circulating anti-CMV immunoglobulin.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Significant pulmonary dysfunction.
- Uncontrolled or unstable diabetes.
- Significant cardiovascular disease including uncontrolled hypertension, congestive heart failure, cardiac arrhythmia, angina pectoris, or a history of myocardial infarction within one year of entry into the study.
- Coagulation or hemorrhagic disorders.
- Any active severe opportunistic infection.
Concurrent Medication:
Excluded:
- Therapy with amphotericin B or fluconazole.
- Any other investigational drug.
- Biologicals including immunoglobulin therapy, granulocyte-macrophage-colony-stimulating-factor (GM-CSF), erythropoietin alpha, or any interleukin.
Patients with the following are excluded:
- Any significant organ system dysfunction as described in Exclusion Co-existing Conditions.
- Any other severe concomitant clinical condition.
Prior Medication:
Excluded within 2 weeks of study entry:
- Therapy with amphotericin B or fluconazole.
- Any other investigational drug.
- Biologicals including immunoglobulin therapy, granulocyte-macrophage-colony-stimulating factor (GM-CSF), erythropoietin alpha, or any interleukin.
- Excluded:
- Prior treatment with monoclonal antibodies derived from any animal species.
Prior Treatment:
Excluded within 2 weeks of study entry:
Purpose
